EGFR and non-small cell lung carcinoma: In a recent case series of 29 patients with non-small cell lung cancer (NSCLC) with disease progression on a first-generation EGFR-directed oral TKI (over 75% had also received cytotoxic chemotherapy) and were noted to harbor EGFR T790M mutation at progression, 13 (44.8%) patients received osimertinib 40 mg orally daily (dose reduced for adverse effects), while the rest were treated with standard dose osimertinib.